KLP Kapitalforvaltning AS acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,800 shares of the biopharmaceutical company's stock, valued at approximately $502,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in shares of Xenon Pharmaceuticals by 0.4% in the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock worth $151,317,000 after acquiring an additional 15,226 shares during the last quarter. Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after purchasing an additional 1,507,135 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after purchasing an additional 905,129 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Xenon Pharmaceuticals by 9.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 848,850 shares of the biopharmaceutical company's stock valued at $33,275,000 after purchasing an additional 70,557 shares during the last quarter. Finally, Jennison Associates LLC lifted its holdings in Xenon Pharmaceuticals by 39.0% in the 4th quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock valued at $31,421,000 after purchasing an additional 224,892 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.
Insider Activity at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the company's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares in the company, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.52% of the stock is owned by insiders.
Xenon Pharmaceuticals Stock Down 7.8 %
Shares of NASDAQ XENE traded down $2.40 during midday trading on Tuesday, hitting $28.23. The stock had a trading volume of 1,608,521 shares, compared to its average volume of 419,061. Xenon Pharmaceuticals Inc. has a 1-year low of $27.56 and a 1-year high of $46.00. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.01 and a beta of 1.21. The company has a fifty day moving average price of $36.23 and a 200 day moving average price of $39.19.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on XENE shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective for the company. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. StockNews.com lowered Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday. Finally, William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $57.38.
Check Out Our Latest Research Report on XENE
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
